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ABSTRACT
Headache is the commonest symptom seen in both primary and secondary care. Vast majority are primary i.e. for which
no underlying cause has been detected. Tension Headaches, Migraine and Cluster Headaches are the most common
primary headache disorders in the population. Although most of the primary headache disorders can be satisfactorily
treated with both acute and preventive medications, those that are refractory to conventional treatment pose a great
challenge to the headache physician. Moreover some patients are not able to use traditional treatment due to intolerance and co-morbidities. Neurostimulation is a treatment modality that has been used in other neurological disorders
such as movement disorders, multiple sclerosis and chronic neuropathic pain and there has been emerging evidence
to its usefulness in primary headache disorders. These range from being invasive treatments like deep brain stimulation to minimally invasive one like occipital nerve stimulators. Non-invasive neurostimulation is gradually emerging as
a potential non-pharmaceutical option in managing primary headache disorders. The article reviews the evidence of
Neurostimulation in primary headache disorders with a view to ascertain its efficacy and safety.
KEY WORDS: Neurostimulation, Occipital nerve stimulator, peripheral nerve stimulator, Deep brain stimulation,
transcranial magnetic stimulation, refractory headaches
INTRODUCTION
Primary headache disorders affect almost half of population; although primary chronic headaches occur only in around
3%. However, these forms of headache prove to be quite challenging for our conventional therapeutic modalities, due
to high prevalence of acute analgesics misuse, the relatively-unimpressive response rate to available pharmacological
agents which reaches 50% in the best cases as well as the adverse events profile 1. Neurostimulation is a novel therapeutic approach, which has been tried in different neurological conditions, namely movement disorders 2, chronic
pain3, and epilepsy4. In this article, we review the evidence for neurostimulation in different primary headache disorders, using diverse modalities of delivery that range from invasive ones like deep brain stimulation, less invasive
techniques such as occipital nerve stimulation and sphenopalatine stimulation, to the non invasive modalities such as
transcranial direct current stimulation, transcranial magnetic stimulation and the vagal nerve stimulation.
INVASIVE NEUROSTIMULATION
Deep brain stimulation (DBS) for Trigeminal autonomic cephalalgias (TACs):
Hypothalamic deep brain stimulation has been used as potential therapeutic target for chronic cluster headache due to
evident hypothalamic hyperactivity during cluster attack 5. A significant responder rate (pain free or 50% responder rate)
has been noted in about 64% across all the cases done worldwide using open-label bases6-19. A randomised, doubleblind, placebo-controlled trial, using active and sham stimulation, has failed to produce comparable results, likely due
to the short blinding phase, as significant responder rate of 60% has been noted during the subsequent open-label
phase 16. It is worth mentioning that majority of patients experienced re-emergence of cluster attacks once their stimulator has stopped working which emphasise the role of stimulation as a form of symptomatic therapy. The positive results
of DBS in treating chronic cluster headache has encouraged researchers to explore its potentials for other types of TACs
with positive results in 3 cases of Short lasting unilateral neuralgiform headache with conjunctival injection and tearing
(SUNCT) where patients attained significant reduction in their attacks’ frequency after at least one year of stimulation2022
. Another positive result has been achieved with one case of chronic paroxysmal hemicranias23.
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tal nerve is a branch of the C2 spinal root. The lesser
occipital nerve is composed of branches of the C2,
C3 spinal roots. The medial branch of the posterior
division of the C3 root gives off a branch called the
least occipital nerve. ONS is used for many intractable headache syndromes such as occipital neuralgia,
migraine, cluster headache and some of less
common conditions like SUNCT and hemicranias
continua (HC). There is anatomical and functional
correlation between trigeminal and cervical afferents
called the trigeminocervical complex from the
trigeminal caudal nucleus to at least the C2 segment
31
, hence ONS can modulate pain in the areas not
only in the occipital nerve distribution but also in the
trigeminal nerve distribution.

DBS is not a risk-free procedure, various adverse
events have been reported including fatal intracerebral haemorrhage (3%), intraoperative panic
attacks induced by autonomic disturbance19, intraoperative TIA with hemiplegia lasting 5 minutes6, ocular
movement disturbances18-19, tremor 17, and
sneezing24. A positive effect of DBS has been an
improved quality of sleep likely to be related to reduction of the nocturnal attacks frequency 6.
PERIPHERAL NERVE STIMULATION
The pain modulation following an electrical stimulation not only has direct effects on stimulated nerve
but also a secondary effect on the central nervous
system. The Melzack-Wall gate control theory states
that, ‘there is an inverse relationship between activity
in small diameter nociceptive afferents and large
diameter nerve fibers’. Large diameter nerve fibre
stimulation results in reduction of the small diameter
fiber nociceptive input and elevation of pain thresholds which in turn results in pain relief 25. Hence in
the Occipital nerve stimulation (ONS), electrical
stimulation of C2, C3 nerve branches are expected to
reduce the small diameter nociceptive fibers activity
causing pain relief. According to gate control theory,
this interaction occurs in the dorsal horn of spinal
cord, but some studies suggest that neurostimulation alters the conduction velocity and the amplitude
of both the A-alpha and beta and the A-delta waves
with the more slowly-conducting A-delta component
showing the greatest changes. This direct alteration
of peripheral nerve activity distal to the first synapse
in the spinal cord might contribute to the mechanism
of pain relief 26.
Peripheral nerve stimulation also has secondary
central nervous system effects. Some of the animal
and human studies have shown that the trigeminocervical pathway is multidirectional, therefore
activation of one part of the system results in activation of other parts. Both mechanical and electrical
stimulation of the superior sagittal sinus results in
activation of the neurons that extend from trigeminal
nucleus to C1,C2 dorsal horns27, 28. The greater
occipital nerve stimulation has also been shown to
increase the metabolic activity of the dorsal horn at
C1,C2 and trigeminal nucleus caudalis 29. Positron
emission tomography (PET) studies of chronic
migraineurs treated with bilateral ONS showed
central nervous system effects including alteration of
the thalamic activation that resulted in pain relief 30.
Occipital nerve stimulation (ONS)
There are three nerves that innervate occipital
region, namely the greater occipital nerve, lesser
occipital and least occipital nerve. The greater occipi-
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IMPLANTATION TECHNIQUES
ONS treatment was introduced by Weiner and Reed.
There are various implantation techniques
described32. Implantation procedure can be done
under local or general anaesthesia. ONS is typically
done with equipment that is normally used for spinal
cord stimulation (SCS).
Medication overuse headache should be ruled out
prior to offering ONS. Often positive but transient
response to occipital nerve blockade has been used
prior to offering ONS trial although evidence suggests
that this may not be a good predictor33. Many centres
are using 5-7 day percutaneous stimulator trial to
test the efficacy and tolerability before permanent
implantation. The predictive values of both methods
are questionable 34. Permanent implantation can be
undertaken with midline or retromastoid approach
and is usually done in two steps. The first step is
conducted under local anaesthesia to test the stimulation and optimal placement of electrodes followed
by insertion of the remaining ONS under general
anaesthesia. It can be successfully implanted under
general anaesthesia as a single procedure with the
same desired outcome 35.
There is a wide variation in the stimulation settings
used, with the amplitude ranging from 0.1 to 10 V,
the frequency ranging from 3 to 130 Hz and pulse
width ranging from 90 to 450 ms36. Further studies
are needed to establish impact of specific parameters on outcome. Alternatively, there are miniaturized devices called ‘Bion’ which can be implanted
over the occipital nerves 37. Recently Trentman and
colleagues described the implantation technique and
the stimulation parameters of the bion microstimulator in nine patients with medically intractable primary
headache disorders 38. Their results showed that the
bion may provide effective occipital stimulation
without requiring anchoring or tunnelling of exten-
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with IHS defined chronic migraine refractory to pharmacological therapy. Each patient had pain involving
the C2 distribution with or without pain in the other
regions of the head. All patients had undergone a
5-7 day percutaneous stimulator trial prior to permanent placement. 3 had unilateral stimulator and 5
had bilateral stimulation with percutaneous cylindrical leads. Patients were able to change the stimulator parameters and also medication changes during
their follow up period. At mean 18 months follow up,
3 month headache frequency reduced from 90 to 60
days while the VRS reduced from 6.8 to 4.5. Patients
also reported significant reduction in disability and
depression after the ONS operation. Complications
include 3 patients requiring revision for lead migration and 1 required IPG revision. Neck stiffness and
incision site pain was also reported 41.
ONS for the treatment of intractable chronic Migraine
(ONSTIM) was a multicentre, randomised, single
blind, controlled study by Saper et al 42. The study
recruited 66 patients who met the revised International Classification of Headache Disorders (ICHD-II)
criteria and those who had successful response to
occipital nerve blocks. The average duration of
migraine was 22 years (1-51 years) and chronic
migraine for an average of 10 years prior to the study
enrolment (range 1-30 years). Patients were
randomised in a ratio of 2:1:1 to adjustable stimulation, preset stimulation and medical treatment. The
responder rate was defined as 50% reduction in
headache days/month or at least 3 point drop (on
VRS 0-10) in pain intensity at 3 months. The
responder rate was 39% in the adjustable stimulation group compared with 6% in the preset group and
none in the medical treatment group. Complication
of lead migration occurred in 12 of 51 patients
(24%). It was concluded that Occipital nerve blocks
are not predictive of ONS response. There were
limitations to this study as blinding was not possible
with ONS trials and paraesthesia resulting from
stimulation and the feasibility to change the stimulator parameters gave some placebo effect in adjustable stimulator group. However, the results overall
suggest that ONS might represent a therapeutic
option for some patients with chronic migraine.
Further studies are needed to assess therapeutic
response and complications 42. Weiner and Reed
reported the benefit of ONS in a series of patients
with intractable occipital neuralgia but detailed
phenotyping in some of these patients through
functional imaging revealed that they had chronic
migraine 43, 44.

sions to remote power sources. Other advantage is
reduced risk of lead migration. However it needs
frequent recharging and may get encapsulated
requiring increased energy to stimulate occipital
nerve. The efficacy and safety need to be established
with further studies.
EFFICACY AND SAFETY OF ONS
ONS has been studied in primary headache
syndromes although it is also used in secondary
headaches such as cervicogenic headache, post
traumatic headache and occipital neuralgia. Popeney
and Aloused C1 through C3 peripheral nerve stimulation to treat 25 Patients who met the International
Headache Society (IHS) criteria for episodic migraine
refractory to pharmacological treatments. Mean
duration of headache was 10 years (range 1-30
years). All patients completed a successful5-7 day
trialof outpatient stimulation with an externalised
quadripolar electrode system before a permanent
implant. The mean stimulation parameters were 55
Hz frequency, 3.2 V voltage, 400 µs. 60% patients
used the stimulator intermittently and 40% used it
continuously. Patients were followed up for 18
months (range 8-36 months). 88% reported at least
50% reduction in headache frequency or severity
after ONS was implanted. The average 3 month
headache frequency reduced from 76 days pre ONS
to 38 days post ONS. The Visual rating scale (VRS
0-10) reduced from an average 9.38 to 5.72. The
average migraine disability assessment score
reduced from grade IV (severe) to grade I (mild).
Medication usage reduced to less than 15 doses per
month for residual symptoms. Complications
included traumatic lead migration in 6, spontaneous
migration in 3 and infection in 1 patient 39.
Oh and colleagues studied ONS in 10 patients with
transformed migraine refractory to preventive and
physical treatments. The mean duration of headache
was 12 years (range 2-25 years). 9 patients had
shown complete but transient pain relief with greater
occipital nerve block and 1 patient had partial (80%)
relief. 7 patients had previous success with dural
percutaneous cylindrical electrodes that migrated. All
10 patients were then implanted with dual paddle
style electrodes. At one month 9 out of 10 patients
reported more than 90% pain relief while 1 reported
75-90% improvement. At 6 months, 7 patients
reported more than 90% relief, 2 had 75-90% and 1
was lost to follow up. All the patients were happy to
undergo the operation again. Complications included
infections in 2 patients which led to removal in 1
patient with replacement 2 months later 40.
Schwedt and colleagues studied ONS in 8 patients
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ONS IN CLUSTER HEADACHE
Magis et al in their study of 8 patients with medically
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tively. At follow up, 3 month headache frequency had
dropped from 90 days to 10 and 12 days respectively.
Pain severity had reduced from VRS 7.5 to 3-7. Both
patients had lead migration and one had infection 37.
Burns et al studied 6 patients with HC using bion
device. It showed improvement in pain ranging from
30% to 80-95%. One patient had worsening of pain
by 20%. Adverse effects were mild and associated
with transient overstimulation. Authors later reported
that the one patient who got worse had chronic
migraine after going through the medical notes and
treatment response review 48.
ONS in Short lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing (SUNCT)
and Short lasting Unilateral Neuralgiform headache
Attacks with cranial autonomic features (SUNA)
There is limited evidence to suggest the usefulness in
treating SUNCT and SUNA.
Matharu and Colleagues did a study of 7 patients
with medically intractable SUNCT and one patient
with SUNA treated with bilateral ONS showing some
benefit. No major side effects were reported 50.

intractable cluster headache showed that treatment
with ONS was beneficial. Weekly headache
frequency reduced from 13.4 pre to 2.8 post ONS.
Attack intensity reduced from 2.62 to 1.47 post ONS
(scale of 4, 1 being mildest to 4 being worst pain).
Majority of the patients who responded to ONS were
able to reduce their preventative medication but only
one was able to stop them completely. Lead
displacement and electrode migration were reported
in one patient each [45]. Burns et al in their study of
14 patients with medically intractable cluster headache using bilateral ONS showed variable results but
yet demonstrating that it is fairly beneficial in 10 out
of 14 patients. There was approximately 20-30% to
90% improvement in headache reported in this
study. Lead migration was reported in 29% of
patients, other complications were muscle recruitment, neck stiffness, skin discomfort, superficial
infection, painful paraesthesias 46, 47.
Schwedt et al reported ONS use in 3 patients with
chronic cluster headache. It was a small series and
the efficacy of ONS was low. Headache frequency did
not change and as a matter of fact one patient
reported an increase in frequency. Headache severity
in two patients had reduced from VRS 8 to 5 and 8
to 3.5 respectively. Lead migration was the main
adverse event 48.
Although the above published open label studies
show some benefit from ONS in chronic cluster
headache, there were a few drawbacks in study
design, patient selection, and outcome measurement. Hence, Leone et al made recommendations
on the criteria for neurostimulation in primary headaches. These include daily or almost daily headache
frequency for 2 years, all the medical therapy to be
tried for sufficient period of time unless contraindicated, post implant follow up should be at least a
year, psychological assessment should be done prior
to implantation surgery, patients to maintain
prospective headache diary to document frequency,
severity, duration of headache episodes and any
painkillers consumed, quality of life measurements,
self assessment of pain 49.

NON-INVASIVE NEUROSTIMULATION
TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
tDCS is a non-invasive modality that uses a weak
direct current in order to change the resting neuronal
potential, it utilises two types of stimulation, either
cathodal (inhibitory) or anodal (excitatory) stimulations which can modulate the function of the stimulated part of the brain to achieve a desired effect. The
effect of tDCS is thought to be restricted to the
cerebral cortical potentials, studies have shown that
anodal tDCS did not change the nociception-specific
blink reflex which usually reflects brainstem electrophysiological changes 51. Animal models of cortical
spreading depression (CSD) (a key mechanism in
migraine with aura) showed that this process could be
modulated using the above mentioned technique 52.
The above mentioned findings have paved way to
study the effect of cathodal tDCS application on the
primary visual cortex, over 6 weeks, in 26 patients
with migraine with aura and compare it to sham
stimulation. Interestingly, the improvements of the
study parameters were not statistically significant
except for migraine intensity 53. Anodal tDCS of
primary motor cortex has been used in different pain
syndromes with considerable success; similar result
were found in 13 subjects with chronic migraine,
however it took about 3 months for pain intensity and
period to improve 54. The largest study using tDCS
during the migraine attack in 62 patients showed a
reduction in pain intensity that is comparable to
sham stimulation 55.

ONS IN HEMICRANIA CONTINUA (HC)
There are few small series suggesting some benefit in
hemicrania continua. Schwedt el al 37 described a
patient with HC who had discontinued indomethacin
due to intolerance and had unilateral bion device
implanted. There was significant improvement to
pain free state at baseline with superimposed severe
headaches five times in 3 months.Same group of
colleagues treated two patients with a diagnosis of
HC who had developed intolerance to indomethacin
with ONS, one unilateral and one bilateral respec-
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TRANSCRANIAL MAGNETIC STIMULATION (TMS)
TMS has been an investigative tool in clinical neurophysiology for the last two decades; however its
potential utilisation in treating migraine could revolutionise the way we approach migraine treatment in
the future. TMS utilises a rapidly changing magnetic
field (delivered by a single or multiple pulses) to
induce hyperpolarisation or depolarisation in the
cerebral cortex, this is best applied to migraineur with
aura due to CSD which is an intense depolarization of
neuronal and glial membranes57. CSD indicates
underlying brain hyperexcitability particularly the
occipital cortex excitability that has been demonstrated in migraine with aura56, 58,59. CSD in animal
studies has shown to result in neurogenic inflammation and activation of nociceptive trigeminal afferents
60
. The animal studies with transcranial magnetic
stimulation has shown to inhibit CSD and hence
potentially terminate the aura and reduce the duration or severity of migraine in those with migraine
aura 61. Commercially available devices have a
microprocessor-controlled power source that is
connected to an insulated wire coil. The stored
energy is rapidly discharged through the wire coil in
response to a trigger. This results in high current
pulse passing through the coil creating a transient
magnetic pulse lasting less than 1 millisecond. When
coil is placed against the head, the transient
magnetic field passes through the scalp and skull,
inducing an electrical current in the underlying
cortex. The peak magnetic field strength of a conventional device is 1.5-2 Telsa comparable to fields from
clinical magnetic resonance imaging (MRI) scanners.
The US Food and Drug Administration characterize
TMS by frequency. Low frequency TMS refers to a
stimulus delivered less than 1 pulse per second and
this is not considered to be a serious risk to health
and safety. High frequency TMS refers to a stimulus
that is delivered at 1 pulse per second or more and
this is considered as a potential risk. Effect of single
pulse stimulation has been evaluated in migraine
using migrainous pain response and pain recurrence
in 24 hours, In 42 patients (migraineurs with and
without aura) using two single pulses of high and low
intensities; migraine intensity has improved with both
intensities and up to one third of patients did not
experience migraine recurrence in 24 hours 62. The
above results led to study the outcome of the same
technique on 164 migraineurs with aura using a
sham-controlled design; pain freedom at 2 hours
was significantly better in the TMS arm; the headache recurrence rate at 1 and 2 days after treatment
were better in the TMS arm, however the use of
acute analgesics and consistency of response was
comparable between groups63. Cortical responses
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from repetitive TMS (rTMS) have been sustained for
a longer periods than those produced by single pulse
stimulation which found the theory bases for usage
of rTMS in chronic pain syndromes such as fibromyalgia and chronic migraine. Dorsolateral prefrontal
cortex is believed to affect migrainous pain pathogenesis negatively, which makes a target for rTMS
studies. Results of rTMS on chronic migraine are
inconsistent, with a sham-controlled study involving
a total of 11 patients showed a sustained reduction
in attacks frequency, headache index, and acute
analgesics use for 2 months 64. However this positive
outcome could not be attained in another shamcontrolled trial in 13 patients 65, 66.
NON CLINICAL SAFETY DATA OF TMS ON BRAIN
AND NERVES
An animal studies have shown that there is little or
no neural injury, 67 no delirious effect on the central
nervous system,68 and no short or long term deficits
in higher cerebral function or any other adverse
events were reported.69
CLINICAL SAFETY DATA OF TMS
There are no short or long term sequelae reported
with the use of TMS in normal individuals or those
with neurological disorders although few adverse
events are described. Discomfort of scalp which is
mild to moderate in severity has been reported and it
respond to analgesics 70. Minor adverse effects like
dizziness, drowsiness, fatigue, increased nausea,
itchy or tingly sensation, increased headache and
neck pain have been reported. These adverse events
are mild and short lasting. No serious adverse events
have been reported 63, 71-74. One of the tolerability
study where subjective response to TMS treatment
was evaluated in children. They were asked to
complete a questionnaire to rank order their TMS
experience with few ordinary life encounters. The
children felt TMS was less enjoyable than watching
television but more enjoyable than a long car ride 75.
Doses up to 12,960 pulses per day were safe and
tolerable in healthy men and showed no effect on
sleep 76. Overall, sTMS or rTMS is regarded as safe
and tolerable treatment both in normal and those
with neurological disorders provided there are no
exclusion criteria such as presence of metal anywhere
in the head excluding the mouth, skull defects, intracardiac lines, and cardiac pacemakers 77.
POTENTIAL SAFETY CONCERNS WITH TMS
RISK OF SEIZURE
There is a hypothetical risk of inducing an epileptic
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seizure. It can selectively activate the epileptic focus
or foci in patients with medically intractable complex
partial seizures 78. Schrader et al reported that crude
risk of TMS associated seizure in patients with
epilepsy ranged from 0.0%-2.8% for sTMS and
0.0%-3.6% for rTMS. The nature of reported seizures
in all cases was similar to each patient’s typical
seizure. There were no long term sequelae79. Those
with subcortical lesions did not have seizures 80.
Concurrent use of medications that lower the seizure
threshold such as tricyclic antidepressants or neuroleptics, has been thought to be a potential risk factor
to induce seizure 80. Patients with stroke may have
a risk of seizure after the use of TMS 81.

mals [88]. It was also concluded that epidemiologic
evidence of an association between magnetic fields
and pregnancy outcome is not supported 89. The
frequency of the sTMS device meets the definition of
very low frequency (ie, <100,000 Hz) 55, 59. Further
research studies are necessary to fully assess the
safety data in pregnancy. Further clinical data does
not show any significant effect of TMS on brain
tissue, blood pressure, pulse rate, hypothalamic
limbic structures hence no effect on cortisol or
prolactin levels, no transient or permanent effect on
hearing 91.
FRONTIERS OF NEUROSTIMULATION
Stimulation of the sphenopalatine ganglion, through
its important connections to the hypothalamus and
the trigeminovascular complex, was found to be effective in aborting around 50% of cluster and migraine
attacks in two initial studies 92, 93 with further studies
being conducted to verify initial findings. The stimulator is implanted in the pterygopalatine fossa which
gets activated by a hand-held controller by putting it
on the cheek where the stimulator is located.
Following the emergence of TMS, many novel non
invasive modalities of neurostimulation are being
considered e.g., Cefaly which utilises the supraorbital
nerve stimulation for stopping migraine attacks.
Another device, GammaCore is currently going
through a randomised double-blind controlled trial in
Europe on patients with cluster headache both
during attack and as preventive treatment. GammaCore works through stimulation of vagus nerve to
exert its effect on acute attacks. It utilises the
findings from previous retrospective studies in
patients with epilepsy who achieved a significant
improvement in headaches after having a vagal nerve
stimulator implanted for refractory epilepsy 94, 94.

RISKS TO THE ATTACHED OR IMPLANTED ELECTRONIC EQUIPMENT
The risks of sTMS to implanted or attached electronic
devices have been studied both empirically and theoretically by Cadwell. In most cases, the effects of the
magnetic field on metal objects are minimal.
However, TMS is contraindicated in those with
cardiac pacemakers and other implanted metallic
objects with electrically conductive properties as it
can dislodge the objects or induce electrical
currents.82 Study of TMS use in patients with spinal
cord stimulator pulse generators implanted in the
lower abdomen has been proven safe, both when the
device is on and off 83.
Patients with Deep Brain Stimulator (DBS) who
received TMS treatment, no damaging stimuli to the
brain or damage to the DBS was observed but it was
noted that inadvertent administration of TMS directly
over the implanted DBS could result in malfunction
84
. In those with Vagus nerve stimulator (VNS) the
study has shown that sTMS use does not result in
nerve stimulation or damage and the function of
pulse generator was unaffected85.

CONCLUSION
The future of primary headache disorders looks promising. The invasive nature and the high cost of DBS
and ONS makes it a very last choice for intractable
primary headache disorders, the arrival of noninvasive treatment may well change the way we treat
headaches. sTMS is currently undergoing appraisal
through the National Institute of Clinical Excellence to
evaluate its cost effectiveness in treating migraine
under the National Health Service and the outcomes
are awaited with interest. We are aware of the postmarketing data being collected for sTMS in the UK and
the results will indicate its effectiveness and safety in
the real life setting. If successful this will open doors
for more devices of similar nature, albeit smaller and
cheaper to overtake pharmaceutical options.

TMS USE IN PREGNANCY
The evidence of safety of TMS use in pregnant
women is limited. There are 2 case reports in which
depression was treated in pregnancy with repetitive
transcranial magnetic stimulation and there were no
adverse effects reported in both mothers and their
babies 86, 87. The Committee on the Possible Effects
of Electromagnetic Fields on Biologic Systems, a
committee of the National Research Council,
reviewed exposure to electric and magnetic fields
concluded that extremely low frequency electric or
magnetic fields exposure do not affect the reproduction and development in animals especially mam-
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